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ABSTRACT
Objective To assess the effects of the neuraminidase
inhibitors oseltamivir and zanamivir in treatment of
children with seasonal influenza and prevention of
transmission to children in households.
Design Systematic reviewand meta-analysis of data from
publishedandunpublishedrandomisedcontrolledtrials.
Data sources Medline and Embase to June 2009, trial
registries, and manufacturers and authors of relevant
studies.
Review methods Eligible studies were randomised
controlled trials of neuraminidase inhibitors in children
aged ≤12 in the community (that is, not admitted to
hospital)withconfirmedorclinicallysuspectedinfluenza.
Primary outcome measures were time to resolution of
illness and incidence of influenza in children living in
households with index cases of influenza.
Results We identified four randomised trials of treatment
of influenza (two with oseltamivir, two with zanamivir)
involving 1766 children (1243 with confirmed influenza,
of whom 55-69% had influenza A), and three randomised
trials for postexposure prophylaxis (one with oseltamivir,
two with zanamivir) involving 863 children; none of these
trials tested efficacy with the current pandemic strain.
Treatment trials showed reductions in median time to
resolution of symptoms or return to normal activities, or
both, of 0.5-1.5 days, which were significant in only two
trials. A 10 day course of postexposure prophylaxis with
zanamivir or oseltamivir resulted in an 8% (95%
confidenceinterval5%to12%)decreaseintheincidence
of symptomatic influenza. Based on only one trial,
oseltamivir did not reduce asthma exacerbations or
improvepeakflowinchildrenwithasthma.Treatmentwas
not associatedwith reduction in overall use of antibiotics
(risk difference −0.30, −0.13 to 0.01). Zanamivir was well
tolerated, but oseltamivir was associated with an
increased risk of vomiting (0.05, 0.02 to 0.09, number
needed to harm=20).
Conclusions Neuraminidase inhibitors provide a small
benefit by shortening the duration of illness in children
with seasonal influenza and reducing household
transmission. They have little effect on asthma
exacerbations or the use of antibiotics. Their effects on
theincidenceofseriouscomplications,andonthecurrent
A/H1N1 influenza strain remain to be determined.
INTRODUCTION
During epidemic years, influenza attack rates often
exceed 40% in preschool children and 30% in school
age children.
1 School age children are the main source
of spread of influenza into households. In some influ-
enza seasons,a quarter of children presentingto emer-
gency departments and paediatric clinics with
respiratory symptoms or fever will have laboratory
evidence of influenza.
2 Moreover, complications of
influenza are common in childrenand includerespira-
tory tract infections (acute otitis media, sinusitis, bron-
chitis, bronchiolitis, croup), febrile convulsions, and
exacerbations ofasthma.Acute otitismedia,forexam-
ple, occurs in 20-50% of children under 6 after
influenza.
3 In contrast, deaths from seasonal influenza
are rare. During the 2003-4 influenza season in the
UnitedStates,2.1 permillionchildrendiedfrominflu-
enza or its complications, such as pneumonia.
4 In the
current H1N1 pandemic, about 30% of cases in the
United Kingdom have been in children aged under
10.
5
The primary strategy for control of influenza is
vaccination.
6 Coverage, however, might be low, and
often there is inadequate time to produce and distri-
bute vaccines in response to emerging strains, such as
influenza A/H5N1 and the new variant influenza A/
H1N1 (Mexico). Therefore, current control strategies
include using antiviral medications for preventing
spread, as well as for treating infected individuals.
Because amantadine and rimantidine are effective
only against influenza A, are limited by drug resis-
tance, and have poor tolerability, they have been
replaced by neuraminidase inhibitors.
7 Oseltamivir
(Tamiflu) is administered orally and in the UK is
licensed for the treatment and postexposure prophy-
laxis of influenza in children aged over 1. Zanamivir
(Relenza) is inhaled as a dry powder and is currently
licensed in the UK for the treatment and postexposure
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For treatment to be effective, current guidelines for
treatingseasonalinfluenzastatethatoseltamivirshould
be administered within 48 hours and zanamivir within
36 hours of onset of symptoms.
8
The last updateof our Cochranereview of thistreat-
ment was in 2005 and included three treatment trials
and one prophylaxis trial.
9 We need an accurate, up to
date assessment of the benefits and harms of oseltami-
vir and zanamivir so that national bodies, clinicians,
and parents can make evidence informed decisions
about treating and preventing influenza in children.
Weassessedthe currentevidence forthe effectiveness,
safety, and tolerability of neuraminidase inhibitors for
the treatment and prevention of influenza in children.
METHODS
Eligibility and search strategy
We included all published and unpublished rando-
mised controlled trials that compared the use of neur-
aminidase inhibitors in the treatment and prophylaxis
ofinfluenzainchildrenaged12andunderthatwecon-
sidered sufficiently free from bias. There were no lan-
guage restrictions. We searched Medline (1966 to 1
July2009),Embase(1980to28June2009),the clinical
trial registries of the manufacturers of oseltamivir and
zanamivir(GlaxoSmithKlineandRochePharmaceuti-
cals, respectively), the Cochrane central register of
controlled trials ( Cochrane Library 2009, Issue 2),
andwww.controlled-trials.com(ameta-registryofran-
domised controlled clinical trials that includes the
ISRCTN register). Search terms were “relenza” OR
“zanamivir” OR “tamiflu” OR “oseltamivir” OR
“neuraminidase inhibitor”. We also hand searched
reference lists of retrieved papers, relevant NICE
guidelines, and technology reports from the UK
Health Technology Assessment programme.
81011The
two pharmaceutical manufacturers provided us with
unpublished data,and we contactedauthorsforclarifi-
cation as needed.
Assessment of risk of bias
UsingtheCochrane“riskofbias”tool,
12weassessedall
studiesforthe quality orappropriatenessof allocation,
blinding, and management of incomplete outcome
data and the completeness of reporting of outcomes.
We also evaluated baseline differences and methodo-
logical issues.
Data abstraction
Twoauthors(MS-S,MT)independentlyextracteddata
from included trials, including year, participants (age
range, inclusion criteria, influenza test results), inter-
vention, and results (outcome measures, effect, signifi-
cance, adverse events). Disagreements in extracted
data were resolved by discussion with a third review
author (CH). Two authors (MS-S, MT) assessed trial
quality. As the incidence of microbiologically con-
firmed influenza in participants recruited with influ-
enza-like symptoms is variable, we analysed efficacy
separatelyforallparticipantswithinfluenza-likesymp-
toms(“clinicalinfluenza”)andforthosewithmicrobio-
logically confirmed influenza (“confirmed influenza”).
We sought data on primary outcomemeasures of time
to resolution of the illness in treatment trials and the
attackrateofsymptomaticinfluenzainchildrenduring
the period of prophylaxis in prevention trials. Second-
ary outcome measures included time to resolution of
individual symptoms; time to return to school, day
care, or normal activity; effect on respiratory function
in children with asthma; and adverse events.
Data analysis
We extracted the median number of days, with 95%
confidence intervals as available, to resolution or
improvement of clinical features of influenza, includ-
ingglobalchange.Whenappropriatewepooledglobal
change scores. We calculated risk differences and 95%
confidence intervals for dichotomous outcomes and
used the I
2 statistic to measure the level of statistical
heterogeneity for each outcome.
13 When no heteroge-
neity was detected, we performed a random effects
meta-analysis.Whentherewassubstantialheterogene-
ity (I
2>50%), we considered possible explanations for
this and considered not combining results. We used
sensitivity analysis when necessary to investigate the
contribution of individual trials to any heterogeneity.
Subgroup analyses included type of neuraminidase
inhibitor and children with clinical or confirmed influ-
enza. We used Review Manager version 5.0 for statis-
tical analysis.
RESULTS
We identified 4917 articles (fig 1), and two authors
independently reviewed 35 full text articles to identify
those that met inclusion criteria. One further unpub-
lishedtrialwasfoundfromtheGlaxoSmithKlineregis-
try.
w1 Seven randomised controlled trials met our
inclusion criteria; four of these were studies of treat-
ment of influenza
w1-w4 and three of postexposure pro-
phylaxisofinfluenzacontactsinhouseholds.
w5-w7Sixof
theseventrialsusedclinicalcriteriaforenrolment,
w2-w7
with virological tests performed at a later date to pro-
duce a post hoc group of confirmed cases; one used
near patient testing for influenza at enrolment.
w1 One
trial confirmed the presence of influenza with near
Potentially relevant records identified and screened (n=4917)
Records retrieved for more detailed assessment (n=35)
Trials eligible for inclusion (n=7)
Excluded (n=28):
  Not an RCT (n=19)
  Comparison not focus of review (n=2)
  Not in children (n=5)
  Not in community (n=1)
  Unable to obtain data (n=1)
Not relevant based on titles and abstract (n=4882)
Fig 1 | Flowchart of search results
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received influenza vaccination in the current season.
w2
Two of the treatment trials tested inhaled zanami-
vir
w1 w2 and two tested oral oseltamivir
w3 w4 in a total
of 1766 children, of whom 1243 had confirmed influ-
enza (table 1). Threetrials recruitedotherwise healthy
children,
w1-w3 while one specifically recruited children
with asthma.
w4 In the three treatment trials that
reported influenza type, 55-69% of participants had
influenza A.
w2-w4 The treatment trials reported the pri-
mary outcome measure of time to resolution of influ-
enza in two ways: median time to resolution of illness,
whichwasacompositeoutcomecomprisingresolution
or alleviation of symptoms and resolution of fever and
returntoschoolornormalactivity
w3 w4;and/ormedian
time to resolution or alleviation of symptoms of influ-
enza (including cough, fever, muscle and joint aches,
sore throat, headache, and fever).
w1-w4 Two trials
w3 w4
used the Canadian acute respiratory infection and flu
scale (CARIFS).
14
For postexposure prophylaxis, we identified two
trials of zanamivir
w5 w6 and one trial of oseltamivir,
w7
which involved a total of 863 paediatric contacts (427
intervention,436control)(table 2).Allthreetrialsran-
domised households as units to receive the same treat-
ment. The drug given to the index case varied in all
trials. In the oseltamivir trial all index cases received
the active drug
w7; in one of the zanamivir trials the
index cases were given the same treatment as the
household (zanamivir or placebo)
w5; and in the other
zanamivirtrialtheindexcasedidnotreceiveanystudy
drug.
w6 The primary outcome measured in these trials
was the attack rate of symptomatic influenza in chil-
dren during the period of prophylaxis.
Assessment of quality of trials
Only one treatment trial reported sufficient detail of
the methods to be judged as high quality.
w2 The three
others did not report sufficient details to determine
whether allocation concealment and blinding were
adequate (table 3).
w1 w3 w4 The three trials of postexpo-
sure prophylaxis were of moderate quality.
w5-w7 Two
hadinsufficientdetailsaboutallocationconcealment
w5
w6andonewasopenlabelled(notblinded).
w7Thebase-
line comparison data for paediatric contacts (all trials)
was not available, but no differences were apparent in
the data for all ages.
Effect of treatment on time to resolution of symptoms,
resolution of illness, and return to school or normal activity
Treatment with zanamivir and oseltamivir provided a
medianreductionintimetoresolutionofsymptomsof
between 0.5 and 1.5 days (table 4). In children with
confirmed influenza, one trial with zanamivir
w2 and
one with oseltamivir
w3 showed significant reductions
inthemediantimetoresolutionofinfluenzasymptoms
Table 1 |Characteristics of the trials of zanamivir and oseltamivir for treatment of influenza*
Trial (drug) Inclusion criteria Exclusion criteria
Age range (years)
(median
intervention,
contol)
Intervention Control
Outcomes
reported
Durationof
follow-up
(days)
Recruited
(vaccina-
ted)
Confirmed
(vaccina-
ted)
Recruited
(vaccina-
ted)
Confirmed
(vaccina-
ted)
NAI30009
w2, 1998-
9, US, Canada,
Europe, Israel
(zanamivir)
Influenza-like
illness of ≤36 hr
duration + temp
≥37.8°C+n o
evidence of
bacterial infection
Immunosuppres-
sed, cystic fibrosis,
underlying
condition that
would prevent data
collection
5-12(mean8.5,8.9) 224 (6) 164 (2) 247 (5) 182 (1) Timetoalleviationof
symptoms,
apyrexia, return to
normal activity.
Incidence of
complications. Use
of antibiotics
28
NAI30028
w1†, 2000-
1, Germany
(zanamivir)
Influenza-like
illness of <48 hr
duration + temp
≥37.8°C+n o
evidence of
bacterial infection.
Rapid influenza test
positive
Not reported 5-12 (7, 8) 176 (NA) 176 (NA) 90 (NA) 90 (NA) Timetoalleviationof
symptoms,returnto
school. Incidence of
complications
5
WV15758
w3,1998-9,
US, Canada
(oseltamivir)
Influenza-like
illness of <48 hr
duration (temp
≥37.8°Candatleast
one of cough or
coryza)
RSV rapid test
positive, HIV
positive,
immunosuppres-
sed, poorly
controlled systemic
illness
1-12 (5, 5) 344 (11) 217 (4) 351 (10) 235 (6) Timetoresolutionof
symptoms,returnto
daycare/school,
apyrexia. Change in
CARIF score
28
WV15759/
WV15871
w4,1998-9,
northern and
southern
hemispheres
(oseltamivir)
Asthma and <48 hr
influenzasymptoms
(temp ≥37.8°Ca n d
cough or coryza)
RSV rapid test
positive, HIV
positive,
immunosuppres-
sed, uncontrolled
renal, vascular,
neurological,
metabolic disease
5-12 (9, 9) 170 (31) 84 (14) 164 (34) 95 (11) Time alleviation of
symptoms,returnto
normal activity,
apyrexia. Change in
peakexpiratoryflow
from baseline.
Change in CARIF
score
28
CARIF=Canadian acute respiratory infection and flu score; RSV=respiratory syncytial virus.
*Zanamivir 10 mg inhaled twice daily for five days, oseltamivir 2 mg/kg (max 100 mg) twice daily for five days
†Not published in peer reviewed journal.
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fidence interval 0.5 to 2.0 days, P<0.001) and from 4.2
to 2.6 days (difference 1.5 days, 0.25 to 2.5 days,
P<0.001), respectively. A further trial of oseltamivir
reported a similar but non-significant reduction in
median time to resolution of influenza symptoms
from 4.8 to 3.8 days (difference 1.1 days, confidence
intervalnotreported,P=0.12).
w4Onetrialofzanamivir
reported a smaller reduction in median time to resolu-
tion of symptoms from 5.5 to 5.0 days but did not
report either a confidence interval or P value.
w1 Only
one trial reported the median time to resolution of
symptoms in children with clinical influenza and
found a significant reduction from 5.0 to 4.5 days (dif-
ference 0.5 days, 0.0 to 1.5 days, P=0.01).
w2
The two oseltamivir trials reported a reduction of
between 0.4 and 1.5 days in the mediantime to resolu-
tion of illness, defined as resolution of all symptoms
and resolution of fever and return to school or normal
activities (table 4). In children with confirmed influ-
enza, oseltamivir provided a significant reduction in
median time to resolution of illness from 5.7 to 4.
2 days (difference 1.5 days, 0.3 to 2.5 days, P<0.001)
in one
w3 trial and a non-significant reduction from 5.6
to5.2days(difference0.4days,confidenceintervalnot
reported,P=0.54)inthesecondtrial.
w4Inchildrenwith
clinical influenza, one oseltamivir trial reported a
reduction in time to resolution of illness from 5.3 to 4.
4days(difference0.9days,0.2to1.9days,P<0.001).
w3
Three treatment trials reported the effects of treat-
mentonreturntoschoolornormalactivity(table 4).
w1
w2 w4 One trial found that children given zanamivir
returned to school or normal activity one day sooner
in those with confirmed influenza (P=0.019), as well as
in those with clinical influenza (P=0.022).
w2 The other
zanamivirtrialreportedthat,bydayfive,36%(62/172)
of children given zanamivir and 28% (25/89) of con-
trols had returned to school or normal activity (risk
difference0.08,−0.04to0.20,P=0.19).
w1Theoneosel-
tamivir trial that reported this outcome found a non-
significantreductioninmediantimetoreturntoschool
from4.8to4.2days(difference0.6,confidenceinterval
notreported,P=0.46)inchildrenwithconfirmedinflu-
enza.
w4
Two trials provided data on the natural course of
confirmed influenza in children.
w2 w3 Resolution of ill-
ness occurred in 75% of children within 8.7 days (90%
within 14.2 days).
w2 Alleviation of all symptoms
occurred in 75% of children within 7.3 days (90%
within 13 days).
w1
Effect of treatment on reduction in cough or fever
Twoofthethree
w1-w3trialsthatreportedeffectsoftreat-
ment on cough showed significant effects: oseltamivir
reduced the median duration of cough by 1.3 days in
children with confirmed influenza in one trial
(P<0.001),
w3 and zanamivir reduced the incidence of
“moderate or severe cough” at day five in children
with confirmed influenza in a second trial
(P=0.001),
w2 but no magnitude of effect was reported.
Of the two trials that reported the median duration of
fever,
w1 w3 there was a significant reduction of one day
in the one trial of oseltamivir (P<0.001)
w3 and a reduc-
tion of 0.5 days (significance not reported) in one trial
of zanamivir.
w1
Effect of treatment on change in asthma severity
One trial of oseltamivir specifically recruited children
with asthma.
w4 Treatment did not reduce the number
of asthma exacerbations in children with confirmed
Table 2 |Characteristics of trials of zanamivir and oseltamivir for postexposure prophylaxis of influenza*
Trial Treatment
Intervention Control
Outcomes
Durationoffollow-
up (days)
Index cases
(confirmed)
Paediatric
contacts
Index cases
(confirmed)
Paediatric
contacts
NAI30010
w5†, 1998-
9, US, Canada,
Finland, UK
Index:zanamivir10mginhaledtwicedailyfor
5daysorplacebo.Contacts:zanamivir10mg
inhaled twice daily for 10 days or placebo.
Excluded: immunosuppressed
163 (78) 135 158 (79) 142 Symptomatic,
laboratory confirmed
influenza during the
10 days on prophylaxis
Index: up to
14 days. Contacts:
28 days
NAI30031
w6†, 2000-
1, 59 sites in
Australasia, Europe,
South Africa, US
Index:nottreated.Contacts:zanamivir10mg
inhaled twice daily for 10 days or placebo.
Excluded: severe persistent asthma, already
had symptomatic influenza
245 (129) 188 242 (153) 183 Symptomatic,
laboratory confirmed
influenza during the
10 days on prophylaxis
Index: 28 days.
Contacts: 28 days
WV16193
w7, 2000-1,
Europe and North
America
Index: oseltamivir 30, 45, or 60 mg based on
age (1-3, 4-5, 6-12) twice daily for 5 days.
Contacts: oseltamivir 30, 45, or 60 mgbased
onage(1-3,4-5,6-12)oncedailyfor10days.
Excluded:immunosuppressed,HIVinfection,
liver, renal, or significant cardiac disease
138 (84) 104 139 (98) 111 Symptomatic,
laboratory confirmed
influenza during the
10 days on prophylaxis
Index: 30 days.
Contacts: 30 days
*Inclusion criteria for all studies: one member with influenza-like illness in household when influenza transmission was confirmed in local area.
†Unpublished subgroup data supplied by manufacturer.
  NA130009
  WV15758
Total
Test for heterogeneity: τ2=0.00, χ2=1.51,
  df=1, P=0.22, I2=34%
Test for overall effect: z=1.74, P=0.08
-0.03 (-0.10 to 0.04)
-0.10 (-0.19 to -0.01)
-0.06 (-0.13 to 0.01)
57.0
43.0
100.0
-0.2 -0.1 0 0.1 0.2
Study or
subgroup
Favours
antiviral
Favours
placebo
Random risk
difference
(random) (95% CI)
Random risk
difference
(random) (95% CI)
Weight
(%)
19
68
87
Antiviral
Events
164
217
381
Total
27
97
124
Placebo
Events
182
235
417
Total
Fig 2 | Incidence of antibiotic use in children with confirmed influenza
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orimprovemedianchangeinpeakflowbetweenstudy
entry and day six (P=0.35) compared with controls.
The trial did, however, identify a small improvement
in the forced expiratory volume in one second (FEV1)
between study entry and day six (median improve-
ment 10.8% v 4.7%, P=0.01). One trial of 471 children
with clinical influenza (of whom 36 (8%) had unspeci-
fied concurrent chronic respiratory conditions requir-
ing regular medication) showed no significant
differenceinasthmaexacerbationsbetweenzanamivir
and control (−0.01, −0.03 to 0.01, P=0.30).
w2 Combin-
ing the results with a random effects model showed no
significant change in asthma exacerbations with neur-
aminidase inhibitor treatment (−0.02, −0.05 to 0.02,
P=0.27, I
2=16%).
Effect of treatment on antibiotic use
Two trials reported the effect of treatment on overall
use of antibiotics. In one, treatment with oseltamivir
was associated with a 10% reduction in overall anti-
biotic use in children with confirmed influenza (risk
difference−0.10,−0.19to−0.01,P=0.03).
w3Incontrast,
treatment with zanamivir did not reduce overall
antibiotic use in children with confirmed influenza
(−0.03, −0.10 to 0.04, P=0.37).
w2 Combining these
results with a random effects model showed a non-sig-
nificant reduction in antibiotic use (fig 2) (−0.06, −0.13
to 0.01, P=0.08, I
2=34%).
Effect of treatment on otitis media
Treatment had no effect on the incidence of otitis
media (risk difference −0.01, −0.04 to 0.02; P=0.92,
I
2=0%) in two trials of children aged 5-12 (who had an
overall incidence of otitis media of 6%).
w1 w4 In a third
trial,
w3 as reported in a separate abstract,
w8 in children
with confirmed influenza treatment with oseltamivir
had no effect on the development of otitis media (con-
firmed with tympanometry) at day 10 in children aged
6-12 (−0.02, −0.11 to 0.06, P=0.57) but did reduce the
incidence of otitis media from 31% to 15% in children
aged 1-5 (−0.16, −0.29 to −0.04, P=0.009).
Effect of postexposure prophylaxis
A 10 day course of prophylaxis with either zanami-
vir
w5 w6 or oseltamivir
w7 was associated with an 8%
reduction (risk difference −0.08, −0.12 to −0.05,
P<0.001, I
2=0%) in the risk of developing confirmed
symptomatic influenza after the introduction of an
index case of clinical influenza into the household.
This equates to a number needed to treat of 13 (9 to
20) to prevent one additional household case of symp-
tomatic influenza (fig 3).
Safety and tolerability of oseltamivir and zanamivir
The four treatment trials reported on tolerability and
adverse events.
w1-w4 Overall reported adherence was
high; 97% of participants took more than eight of the
10 doses of zanamivir,
w2 and 90% took all 10 doses of
oseltamivir.
w3 There was no significant difference in
the number of withdrawals because of adverse events
between either zanamivir or oseltamivir and placebo.
Table 3 |Assessment of methodological quality
Treatment trials Postexposure prophylaxis trials
NAI30009w2 NAI30028w1* WV15758w3 WV15759/WV15871w4 NAI30010w5 NAI30031w6 WV16193w7
Adequate
sequence
generation
Blindly assigned to
zanamivir or placebo in
1:1 ratio by computer-
generated randomisation
schedule
Randomised, but
no further details
given
Block
randomisation by
site. Stratified by
presence of otitis
media
Randomised, no further
details
Randomised by
household, no
further details
Randomised by
household, no
further details
Randomised by
household,nofurther
details
Allocation
concealment
Yes Insufficient detail Insufficient detail Insufficient detail Insufficient detail Insufficient detail Open label
Blinding Randomisation code
broken after study was
completeand all datahad
been entered and verified
in database
Double blind,
“zanamivir
Diskhaler”,
“placebo
Diskhaler”
Double blind,
“placebo or liquid
oseltamivir”
Double blinded,
“oseltamivir or placebo”
Double blind,
placebo inhaler
Double blind,
placebo inhaler
Open label
Incomplete
outcome data
Intention to treat analysis
“primaryanalysisincluded
participants with
incomplete or missing
data”
Intention to treat
analysis,
insufficient details
Appropriate
censoring and
statistical tests
Appropriate censoring
and statistical tests
Intention to treat
analysis, low
discontinuation
Intention to treat
analysis, low
discontinuation
Intention to treat
analysis, low
discontinuation
Free of selective
reporting
Yes Missing95%CIfor
medians
Ye s On lyre po rt edco nf ir me d
influenza and per
protocol populations
Yes Yes Yes
*Not published in peer reviewed journal.
  NA130010
  NA130031
  WV16193
Total
Test for heterogeneity: τ2=0.00, χ2=1.09,
  df=2, P=0.58, I2=0%
Test for overall effect: z=4.68, P<0.001
-0.07 (-0.12 to -0.02)
-0.08 (-0.14 to -0.03)
-0.12 (-0.21 to -0.03)
-0.08 (-0.12 to -0.05)
42.6
41.4
16.0
100.0
-0.3 -0.2 -0.1 0 0.1 0.2
Study or
subgroup
Favours
antiviral
Favours
placebo
Random risk
difference
(random) (95% CI)
Random risk
difference
(random) (95% CI)
Weight
(%)
3
7
7
17
Antiviral
Events
135
188
104
427
Total
13
22
21
56
Placebo
Events
142
183
111
436
Total
Fig 3 | Incidence of confirmed symptomatic influenza in paediatric contacts of index cases with
clinical influenza
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of nausea, vomiting, and diarrhoea. Combination of
data from all four trialsthat reportedvomiting showed
significant heterogeneity (I
2=75%). Subgroup analysis
of the two trials of zanamivir showed no significant
increase in vomiting (risk difference 0.00, −0.02 to
0.02,P=0.82,I
2=0%),
w1 w2whereasthetwotrialsofosel-
tamivir showed an additional one in 20 children trea-
ted would have vomiting (0.05, 0.02 to 0.09, P=0.007,
I
2=0%).
w3 w4 Overall, vomiting occurred in 6.7% (57/
852) of untreated children with clinical influenza.
w1-w4
Inaddition,therewasalowincidenceofnausea(3.4%,
29/852) and diarrhoea (6.6%, 56/852). Neither was
affected by treatment with neuraminidase inhibitors
(−0.01, −0.03 to 0.00, P=0.06, I
2=0%, and −0.01,
−0.03 to 0.00, P=0.16, I
2=0%, respectively).
The two trials of zanamivir for prophylaxis stated
that the incidence of adverse events was similar
betweentreatmentandcontrolgroupsbutdidnotpro-
videquantitativedataonthepaediatricsubgroups.
w5 w6
No deaths were reported.
DISCUSSION
Treatment of influenza in children with zanamivir and
oseltamivirprovided a more rapid resolutionof symp-
toms and resolution of illness generally (resolution of
symptoms and fever and return to school or normal
activity) by between 0.5 to 1.5 days. These reductions,
however, were not all significant, leaving uncertainty
inboththesizeandconfidenceintheseeffects.Because
of inadequate reporting of trial data and heterogeneity
ofthestudieswewereunabletopoolresults.Effectson
individual symptoms were also not consistent. Cough
wassignificantlyreducedbytreatmentintwotrialsand
fever in one of two trials; for both symptoms the mag-
nitude of effect, when reported, was about one day.
Children given oseltamivir or zanamivir returned to
school or normal activity between 0.5 and 1 day
more rapidly than those in control groups. By day
five of the illness, however, only a third of children in
eithergrouphadreturnedtoschoolornormalactivity.
Furthermore,cliniciansshouldbeawarethatforonein
10 children symptoms of influenza might persist for
more than two weeks.
The effects on complications showed inconsistent
results. Oseltamivir and zanamivir showed little or no
effect on the number of asthma exacerbations, with
oseltamivir providing a small improvement in FEV1
in the first six days of illness in only one trial. More-
over,effectsonratesofotitismediawerenodifferentin
childrenaged5-6and12butweresignificantlylowerin
children younger than 5. With a household prophy-
laxis strategy, 13 children would need to be treated
with a 10 day course of zanamivir or oseltamivir to
prevent one additional child developing influenza.
Finally,zanamivirseemedtocausenomoresideeffects
than placebo, whereas oseltamivir was associated with
an additional one in 20 children treated developing
vomiting.
Comparison with existing literature
This review adds to our Cochrane review updated in
2005,whichincludedonlythreetrialsoftreatmentand
one on postexposure prophylaxis.
9 It concluded that
neuraminidase inhibitors were effective in shortening
the duration of illness and showed no significant effect
Table 4 |Effects of treatment on resolution of influenza symptoms, resolution of illness, and return to school or normal activities
Study
Median days to resolution or alleviation of
symptoms Median days to resolution of illness* Days to return to school/normal activities
Antiviral Control Difference (95%CI) Antiviral Control Difference (95%CI) Antiviral Control Difference (95%CI)
Confirmed influenza
Zanamivir:
NAI30009
w2 4.0 5.25 1.25 (0.5 to 2.0),
P<0.001
—— — NR NR 1 day (NA), P=0.022
NAI30028
w1 5.0 5.5 0.5 (NA), P=NA —— — 36% (62/
172)atday5
28%(25/89)
at day 5
RD=0.08(0.04to0.20),
P=0.19
Oseltamivir:
WV15758
w3 2.6 4.2 1.5 (NA) P<0.001 4.2 5.7 1.5 (0.3 to 2.5),
P<0.001
NR NR NR
WV15759/
WV15871
w4
3.8 4.8 1.1 (NA), P=0.12 5.2 5.6 0.4 (NA), P=0.54 4.2† 4.8† 0.5 (NA), P=0.46
Clinical influenza
Zanamivir:
NAI30009
w2 4.5 5.0 0.5 (0.0 to 1.5),
P=0.011
—— — NR NR 1 day (NA), P=0.019
NAI30028
w1 —— — —— — —— —
Oseltamivir:
WV15758
w3 NR NR NR 4.4 5.3 0.9 (0.2 to 1.9),
P<0.001
NR NR NR
WV15759/
WV15871
w4
NR NR NR NR NR NR NR NR NR
RD=risk difference; NR=outcome assessed in study but not results not reported; NA=not available.
*Defined as alleviation of symptoms + return to normal activities + afebrile.
†Median.
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tional treatment trial, found insufficient data to allow
pooling, but the effects reportedare consistent enough
to conclude that treatment results in 0.5 to 1.5 day
reduction in influenza symptoms or illness, or both.
In the present review, we also obtained data of postex-
posure prophylaxis from two additional trials, which
allowsustobemorecertainabouttheeffectoncontact
cases(P<0.001).Asystematicreviewofneuraminidase
inhibitors for treatment and prevention of influenza in
adults concluded that both zanamivir and oseltamivir
provided small beneficial effects for alleviating symp-
toms; the ratio of the median times to resolution
between the treatment and placebo groups were 1.33
and 1.30, respectively.
15 In adults, both drugs were
effective at postexposure prophylaxis in people with
confirmed influenza but not those with influenza-like
illness.
15
Our findings also suggest that any effects present
were less in children with clinically defined influenza
than in those with microbiologically confirmed influ-
enza. This might present a problem in seasonal influ-
enza in primary care, where the accuracy of clinical
diagnosis (without near patient testing) might be
limited.
16 For example, influenza was detected in only
30-39%ofnasopharyngealswabssubmittedforvirolo-
gical surveillance in children attending UK general
practices with influenza-like illness during three suc-
cessive winter seasons.
17 In pandemic influenza, how-
ever, a greater proportion of children presenting with
influenza-like symptoms are likely to have influenza,
which would tend to increase the apparent efficacy of
neuraminidase inhibitors in clinical cases. The differ-
ence in the effect of oseltamivir and zanamivir on
secondary complications of influenza such as otitis
media and the subsequent use of antibiotics might
be due to the low systemic absorption of inhaled zana-
mivir compared with oral oseltamivir, which has 80%
bioavailabilityandgoodpenetrationtomiddleearand
sinuses, or due to the age groups selected for the zana-
mivir trials.
18 Reductions of secondary complications
couldbeanimportantfactorinthedecisiontotreatand
should be balanced with the higher rates of adverse
effects, particularly vomiting, with oseltamivir.
Strengths and weaknesses of review
Our review has some limitations. Firstly, our search
strategy, while comprehensive, might have missed
publishedandunpublishedtrials.Althoughoursearch
was comprehensive and builds on previous Cochrane
search strategies, important negative findings might
not have been published beyond the conference
abstract stage. We have addressed this issue to some
extent by obtaining unpublished data from one manu-
facturer. We are also aware of seven ongoing rando-
mised controlled trials of neuraminidase inhibitors in
children, as well as several studies involving the cur-
rent pandemic strain, which might affect the findings
of this review (table 5). Secondly, study quality was
generally moderate, with only one of seven included
studies rated free from bias, and the quality of the
others was limited by poor reporting. Thirdly, studies
varied both in the outcomes measured and the consis-
tency ofreportingofresults,which severelyhampered
our ability to aggregate results. Fourthly, there were
few data on children with comorbidities, with only a
single trial of children with asthma: trials excluded
“high risk” children such as those who are
Table 5 |Ongoing trials of neuraminidase inhibitors for influenza in children
Identifier Methods Participants Interventions Outcomes Details
NCT00412737 Seasonal prophylaxis for
12 weeks
Transplant recipients. Age >1.
Negative for influenza.
Confirmed influenza
Oseltamivir v placebo Primary: percentage of patients
with laboratory confirmed
clinical influenza
CD: Nov 2008. Hoffmann-La
Roche
NCT00593502 Prevention of otitis media in
young otherwise healthy
children with symptomatic
influenza
Age 1. Healthy children.
Confirmed influenza .Within 24
hours of symptoms
Oseltamivir v placebo Primary: incidence of otitis
media. Secondary: time to
resolution of fever and other
symptoms
CD: June 2009. Hospital District
of Southwestern Finland.
Hoffmann-La Roche
NCT00555893 Treatment <48 h v >48 h after
symptoms
Age >1. Clinical influenza Oseltamivir v placebo Primary: duration of influenza
illness. Secondary: secondary
attack rate, secondary
complications
ECD: Feb 2011. Marshfield Clinic
Research Foundation
NCT00707941 Treatment <48 h v >48 h after
symptoms, and placebo
Age>1.Population:Bangladesh,
urban slum. Confirmed
influenza
Oseltamivir v placebo Primary: duration of clinical
illness, clinical complications
ECD: Dec 2009. International
Centre for Diarrhoeal Disease
Research, Bangladesh
NCT00545532 Standard v high dose
oseltamivir in transplant
recipients
Age>1.Transplantrecipientson
immunosuppression.
Confirmed influenza. Treatment
<48h
Oseltamivir standard v high
dose.
Primary:timetoalleviationofall
clinical symptoms. Secondary:
secondary illness/
complications
ECD: Oct 2010. Hoffmann-La
Roche
NCT00867139 Triple combined antivirals v
monotherapy for influenza A in
immunocompromised
participants
Age ≥7. Immunocompromised.
Confirmed influenza
Amantadine + ribavirin +
oseltamivir v zanamivir or
oseltamivir
Primary: safety. Secondary:
duration of symptoms
ECD: Dec 2010. Fred Hutchinson
Cancer Research Center
NCT00298233 Standard v high dose
oseltamivir in severe or avian
influenza
Age >1 (some centres). Severe
symptoms or avian influenza.
Confirmed influenza
Oseltamivir; standard v high
dose
Primary: negative RT-PCR from
nasal swabs. Secondary:
includes frequency of clinical
failure
CD: Feb 2009. National Institute
of Allergy and Infectious
Diseases
CD=completion date; ECD=estimated completion date.
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tory problems. Fifthly, there was significant heteroge-
neity in the rates of vaccination between the trials,
ranging from 2% to 20%, which might reduce the
apparent efficacy as the severity of influenza illness is
often milder in vaccinated than in unvaccinated
children.
19 Finally, none of the studies was sufficiently
powered to determine the effects of neuraminidase
inhibitors on serious complication of influenza (such
as pneumonia or admission to hospital), and we
found no evidence from these trials on efficacy and
safety in children aged under 1.
Implications for seasonal and pandemic influenza
For children with seasonal influenza neuraminidase
inhibitors seem to have a small effect in terms of redu-
cing duration of illness of between 0.5 and 1.5 days.
There is currently no evidence to single out special
treatment for children with asthma. It is difficult to
knowtheextenttowhichthesefindingscanbegeneral-
ised to children in the current A/H1N1 pandemic. At
present, most cases in children have been mild, but
recommendations in several countries encourage
treatment of children with suspected or confirmed A/
H1N1 flu. While morbidity and mortality in the cur-
rent pandemic remain low, a more conservative strat-
egy might be considered prudent, given the limited
data, side effects such as vomiting, and the potential
for developing resistant strains of influenza.
Use of neuraminidase inhibitors to limit the spread
of influenza is a key component of containment strate-
gies. The evidence of magnitude of this effect (at least
for seasonal influenza) is now clear: 13 people need to
be treated to prevent one additional case. In a
prolonged pandemic, however, those most likely to
be treated (such as healthcare professionals) might
require multiple courses as the number of contacts
escalates.
Further areas for research
In the seven randomised controlled trials currently
under way, six are treatment trials and one a prophy-
laxis trial (table 5). Three of the trials are being under-
taken in immunocompromised children and one in
children in a developing country. These trials might
also provide some data to help guide clinicians and
parents in the current influenza pandemic, as well as
data on effects in children with comorbidities, who
might be at higher risk of complications. Defining the
role of antibiotics in reducing complications from sec-
ondary infections in seasonal and pandemic influenza
must also be a priority as there are observational data
to show that antibiotics provide a small benefit in chil-
dren with seasonal influenza.
20 In the UK and the US
oseltamivir is not licensed for children aged under 1.
This limitation was supported by animal studies that
found that high doses caused death in juvenile but not
adult rats, with a disproportionately high concentra-
tion of the drug found in the brain.
21 We did not find
any randomised trial data in this age group, but we are
aware of two case series in 148 children aged under 1
treated with oseltamivir, which found no mortality or
encephalitis.
2223 In the current pandemic, there is a
pressing need to understand the benefits and potential
adverse effects of these drugs as the current evidence
base supporting this age boundary is limited.
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